Kyle Cromer, PhD
Tuesday, August 23, 2022, 4:00-5:00 pm (San Francisco) Check your time zone
In this session Dr. Cromer will:
- Summarize a three-pronged approach to develop gene therapies to cure alpha thalassemia major (ATM) ex vivo
- Describe one approach in depth − CRISPR/AAV6-mediated genome editing correction strategy
- Discuss future directions that include the potential adaptation of successful ex vivo strategies for in utero and postnatal in vivo delivery
